Investor Concerns Prompt Investigation into Immix Biopharma, Inc. - A Deeper Look

Pomerantz Law Firm Investigates Immix Biopharma, Inc.

The Pomerantz Law Firm is currently investigating possible claims on behalf of investors in Immix Biopharma, Inc. (NASDAQ: IMMX). This investigation is focused on allegations of securities fraud and other unlawful business practices that may involve several of Immix's officers and directors. Investors affected by recent events are encouraged to reach out to the firm's representative, Danielle Peyton, for further insights and support.

Background of the Investigation

On March 30, 2026, Immix Biopharma announced Richard Graydon's appointment as the company’s Chief Medical Officer (CMO). This news was met with optimism among investors, but it was short-lived. On July 20, 2026, Immix disclosed the termination of Graydon, effective July 17, 2026, and cited reasons that were reportedly unrelated to his performance. This announcement set the stage for a troubling revelation just days later, significantly impacting the company's reputation and financial standing.

Reports emerged revealing that Graydon's true identity was Ronald L. Fischer, who had been a fugitive for over 20 years following a rape trial in 2005. This shocking revelation was made public shortly after his termination, raising questions about how Fischer had managed to secure a high-ranking position within Immix.

Financial Impact on Investors

Following the announcement of Graydon's (or rather Fischer’s) termination and the subsequent media coverage regarding his past, Immix’s stock witnessed a steep decline. On the day of the revelations, the stock price fell by $1.45 per share, representing a 14.15% drop, closing at just $8.80 per share. This financial setback has left investors reeling, as many feel blindsided by the sudden turn of events and the implications it might have for the future of the company.

Pomerantz's Role

Pomerantz LLP has a long-standing reputation as a leading firm in corporate, securities, and antitrust class action litigation. Founded by civil rights attorney Abraham L. Pomerantz, the firm has consistently advocated for investors’ rights and has recovered multi-million dollar settlements for victims of securities fraud and corporate misconduct. The firm’s investigation into Immix reinforces its commitment to fighting for justice on behalf of those affected by corporate malfeasance.

This investigation could serve as a formidable class action opportunity for those affected by the drop in Immix's stock price. Investors are advised to remain vigilant and consider their legal options in light of these serious allegations.

Conclusion

As the investigation unfolds, it remains vital for Immix investors to stay informed and consider joining the class action suit to seek possible reparations for their losses. The troubling circumstances surrounding the former CMO's identity and the subsequent drop in stock price highlight the importance of corporate governance and investor transparency. For those affected, resources and legal support are available through Pomerantz LLP, making it crucial to contact them for assistance.

For further inquiries or to join the potential class action, concerned investors can reach Danielle Peyton at Pomerantz LLP at the provided contact details. Investing can be fraught with risks, but with due diligence and proper legal support, investors can navigate these turbulent waters more effectively.